How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

230 results for

Pityriasis Rosea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Clinical variants of pityriasis rosea (Full text)

Clinical variants of pityriasis rosea Pityriasis rosea (PR) is a common erythemato-squamous dermatosis which almost always, is easily diagnosed. Mostly the disease presents in its classical form. However, clinical dermatology is all about variations and PR is not an exception. Variants of the disease in some cases may be troublesome to diagnose and confuse clinicians. Prompt diagnosis and treatment of the condition becomes necessary to avoid unnecessary investigations. We hereby review

2017 World journal of clinical cases PubMed

22. Persistent Pityriasis Rosea: An Unusual Form of Pityriasis Rosea with Persistent Active HHV-6 and HHV-7 Infection. (PubMed)

Persistent Pityriasis Rosea: An Unusual Form of Pityriasis Rosea with Persistent Active HHV-6 and HHV-7 Infection. Pityriasis rosea (PR) is an acute, self-limiting exanthematous disease, associated with the reactivation of the human herpesvirus 6 (HHV-6) and/or human herpesvirus 7 (HHV-7) that usually lasts 6-8 weeks. We studied, from a clinical and virological point of view, 12 patients in whom the features of PR lasted longer than 12 weeks, defining this form of the disease as persistent PR

2015 Dermatology

23. Pityriasis rosea in pregnancy: report of a spousal occurrence and craniosynostosis in the healthy newborn (Full text)

Pityriasis rosea in pregnancy: report of a spousal occurrence and craniosynostosis in the healthy newborn Pityriasis rosea is a papulosquamous disease. It may occur during pregnancy; in this setting, it has occasionally been associated with adverse outcomes.A woman who developed pityriasis rosea at the beginning of her eighth week of gestation is described. The outcomes in newborns delivered by pregnant women who developed pityriasis rosea during gestation are summarized.A 28-year-old woman (...) developed pityriasis rosea during her eighth week of pregnancy. Her husband had pityriasis rosea two months earlier. PubMed was searched for the following terms: conjugal, craniosynostosis, newborn, pityriasis, pregnancy, rosea, sagittal, spouse. The papers were reviewed and the references cited were evaluated.Our patient delivered a healthy male infant after 41 weeks of gestation. He had normal weight, height, and Apgar scores. Isolated sagittal craniosynostosis was diagnosed and was successfully

2016 Dermatology practical & conceptual PubMed

24. The role of interleukin-22 in pityriasis rosea. (Full text)

The role of interleukin-22 in pityriasis rosea. Pityriasis rosea (PR) is an exanthematous disease related to reactivation of human herpes virus (HHV) types 6 and 7. The pathogenesis and cytokine profile of PR are still poorly understood.There is a large amount of evidence indicating a viral aetiology for PR.To measure the serum level of interleukin (IL)-22, a cytokine expressed by T helper (Th)17 cells in patients with PR to explore the possible association of IL-22 with the pathogenesis (...) of the disease.This case-control study enrolled 25 patients with PR (mean ± SD age 20 ± 12 years) and a control group of 25 apparently healthy individuals (mean age 18 ± 12.1 years). Blood samples were collected from both patients and controls to measure serum IL-22. Scoring of PR was performed using the Pityriasis Rosea Severity Score (PRSS).There was a statistically significant difference in IL-22 serum level between the patient and control groups. The IL-22 serum level increased with increase in disease

2016 Clinical & Experimental Dermatology PubMed

25. Pityriasis Rosea: A Comprehensive Classification. (Full text)

Pityriasis Rosea: A Comprehensive Classification. Pityriasis rosea (PR) is an acute, self-limiting exanthematous disease associated with the endogenous systemic reactivation of human herpesvirus (HHV)-6 and/or HHV-7. The disease typically begins with a single, erythematous plaque followed by a secondary eruption with lesions on the cleavage lines of the trunk (configuration of a 'Christmas tree'). The duration may vary from 2 weeks to a few months. Besides the typical presentation of PR

2016 Dermatology PubMed

26. Acyclovir is not effective in pityriasis rosea: Results of a randomized, triple-blind, placebo-controlled trial. (Full text)

Acyclovir is not effective in pityriasis rosea: Results of a randomized, triple-blind, placebo-controlled trial. Acyclovir is considered to be an effective treatment for pityriasis rosea but randomized, blinded, placebo-controlled trials have not been performed.To test the efficacy of acyclovir in pityriasis rosea in a randomized, triple-blind, placebo-controlled trial.Twenty seven patients with pityriasis rosea were randomly allocated to receive placebo (n = 13) or acyclovir (800 mg five times (...) daily for one week) (n = 14). The severity of disease was assessed by the pityriasis rosea area and severity index. Cure was defined as the absence of erythema, with no or minimal scaling.The number of days (mean ± standard deviation) taken for cure was not significantly different between the two groups (placebo 26.54 ± 9.14 days versus acyclovir 33.29 ± 9.49 days; P = 0.0720, t-test; 95% confidence interval of difference -0.65 to 14.14 days).The sample size for the present study was calculated

2016 Indian journal of dermatology, venereology and leprology PubMed

27. Author's Response--The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial. (Full text)

Author's Response--The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial. 25566901 2016 04 06 2018 12 02 0973-3922 81 1 2015 Jan-Feb Indian journal of dermatology, venereology and leprology Indian J Dermatol Venereol Leprol Author's Response--The efficacy of azithromycin in pityriasis rosea: a randomized, double-blind, placebo-controlled trial. 57 10.4103/0378-6323.148573 Pandhi Deepika D Department of Dermatology and STD, University College (...) of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi, India. Verma Prashant P Singal Archana A Sharma Reena R eng Letter Comment India Indian J Dermatol Venereol Leprol 7701852 0378-6323 0 Anti-Bacterial Agents 83905-01-5 Azithromycin IM Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):36-40 24448121 Indian J Dermatol Venereol Leprol. 2015 Jan-Feb;81(1):56 25566900 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Female Humans Male Pityriasis Rosea drug

2016 Indian journal of dermatology, venereology and leprology PubMed

28. Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? (Full text)

Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? Many clinical and laboratory-based studies have been reported for skin rashes which may be due to viral infections, namely pityriasis rosea (PR), Gianotti-Crosti syndrome (GCS), asymmetric periflexural exanthem/unilateral laterothoracic exanthem (APE/ULE

2016 Infectious disease reports PubMed

29. Pityriasis Rosea

Pityriasis Rosea Pityriasis Rosea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pityriasis Rosea Pityriasis Rosea Aka: Pityriasis (...) ( ) Christmas-Tree distribution on back V-Shaped distribution on the chest Individual lesions appear similar to herald patch Small fawn or salmon colored oval s Peripheral scaly collarettes Central clearing Darker skin: Black Children More facial (30% of cases) and scalp involvement Post-inflammatory pigment changes take place in nearly two thirds of patients Variants: Atypical Pityriasis Rosea Pityriasis Rosea Gigantea of Darier Fewer, but larger lesions Inverse Pityriasis Rosea Lesions primarily involve

2018 FP Notebook

30. A position statement on the management of patients with pityriasis rosea. (PubMed)

A position statement on the management of patients with pityriasis rosea. Many clinical trials have been conducted on the treatment of pityriasis rosea (PR). Our aim was to establish a position statement for the management of adults with PR based on the best available evidence. We searched PubMed for all reports on randomized controlled trials for the treatment of PR published in the past 30 years. We retrieved 14 articles reporting randomized controlled trials, and found five which met our

2016 Journal of the European Academy of Dermatology and Venereology

31. Atypical Pityriasis Rosea with Unilateral Presentation (Full text)

Atypical Pityriasis Rosea with Unilateral Presentation Pityriasis Rosea (PR) is a common skin disease and characterized by generalized scaly eruptions typically on the trunk and proximal extremities. Atypical presentations of PR are common and can be a diagnostic challenge for clinicians. Here we present a case of a 26-year-old female who presented with a sudden onset of several asymptomatic, erythematous and scaly plaques on her trunk. Plaques sized 0.5-1cm in diameter that were distributed

2016 Journal of clinical and diagnostic research : JCDR PubMed

32. Red Cell Distribution Width and Mean Platelet Volume in Patients With Pityriasis Rosea (Full text)

Red Cell Distribution Width and Mean Platelet Volume in Patients With Pityriasis Rosea Pityriasis rosea (PR) is an inflammatory skin disorder of unknown etiology. However, it is suggested to be related with the reactivation of human herpes virus 7 (HHV-7) and/or HHV-6. It is sometimes diffucult to distinguish PR from PR-like drug eruptions and other inflammatory disorders, so we need new parameters which are cheap and easy in determining PR. Red blood cell distribution width (RDW) and mean

2016 Journal of clinical medicine research PubMed

33. Narrowband UVB phototherapy in pityriasis rosea. (Full text)

Narrowband UVB phototherapy in pityriasis rosea. Pityriasis rosea (PR) is an acute self-limiting disease. Despite vigorous efforts by generations of researchers since nearly 150 years, present treatment modalities for PR are not very gratifying. Ultraviolet radiation has been recommended in PR, although only a few studies validate this proposal. This study was conducted to explore the therapeutic effect of NBUVB on the symptoms, course, and severity of PR.This study involved a hundred patients

2015 Indian dermatology online journal PubMed

34. Pityriasis rosea of Gibert: immunological aspects. (PubMed)

Pityriasis rosea of Gibert: immunological aspects. More than 200 years after first description and 150 years after complete definition by Gibert, pityriasis rosea (PR) is still a clinical entity with many obscure aspects. Although great interest was focused on aetiology, studies on immunological mechanisms associated with this disease were rather discontinuous. We present a review of the literature on immunological features of PR, aimed to outline a unified picture of currently available

2015 Journal of the European Academy of Dermatology and Venereology

35. Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability. (Full text)

Acyclovir in pityriasis rosea: An observer-blind, randomized controlled trial of effectiveness, safety and tolerability. Pityriasis rosea (PR) is an acute inflammatory dermatosis. The association of human herpes virus 6 and 7 suggests the utility of use of antiviral agents in this disease.To evaluate the effectiveness and safety of acyclovir in the treatment of PR.An observer-blind, randomized (1:1), parallel group, add-on trial was conducted on 24 adult patients with PR. Subjects of both Group

2015 Indian dermatology online journal PubMed

36. Pityriasis Rosea in Children: Clinical Features and Laboratory Investigations. (PubMed)

Pityriasis Rosea in Children: Clinical Features and Laboratory Investigations. Pityriasis rosea (PR) is a common, self-limiting exanthematous disease associated with a systemic reactivation of human herpesvirus 6 (HHV-6) and/or HHV-7. It usually occurs in the second or third decade of life whereas it is uncommon in patients younger than 10 years. We studied the clinical features and virological parameters of 31 children with PR, comparing them with those in adults. Our findings indicate that PR

2015 Dermatology

37. Localised pityriasis rosea-like eruption during radiotherapy. Report of 2 cases. (PubMed)

Localised pityriasis rosea-like eruption during radiotherapy. Report of 2 cases. Pityriasis rosea is a common skin condition that presents acutely with asymptomatic, scaly and oval plaques, usually in a well-recognised distribution over the trunk. Two men developed ovoid, scaly and annular lesions limited to the radiotherapy field during treatment for pelvic malignancies and without a preceding herald patch. Other causes of the eruption were excluded on clinical and pathological grounds (...) and the histopathological features were consistent with a pityriasis rosea-like eruption. In both cases the lesions resolved spontaneously by 8 weeks. These are the first reported cases of a localised pityriasis rosea-like eruption arising during radiotherapy. © 2014 The Australasian College of Dermatologists.

2014 Australasian Journal of Dermatology

38. The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial. (Full text)

The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial. Macrolides are prescribed in the treatment of pityriasis rosea despite conflicting results of the limited number of studies evaluating their role in its treatment.A randomized double-blind placebo-controlled trial was conducted to evaluate the effect of azithromycin on the clinical course of pityriasis rosea.Seventy patients of pityriasis rosea were given either azithromycin (n=35) or placebo (...) (n=35) and were followed-up at 2, 4 and 6 weeks. Pruritus was assessed in both groups using the visual analogue scale (VAS) . Change in the pityriasis rosea severity score (PRSS) and in the VAS were recorded as outcome measures and were compared statistically.The decrease in PRSS from baseline through 2, 4 and 6 weeks within both treatment (P<0.001) and placebo (P<0.001) arms was found to be statistically significant; however, this change was not significantly different in the two groups (P=0.179

2014 Indian journal of dermatology, venereology and leprology PubMed

39. A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea. (Full text)

A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea. Pityriasis rosea is an acute self-limiting skin disorder of unknown aetiology. Recently human herpes virus 6 and 7 has been hypothesized to be the cause of pityriasis rosea.To determine the efficacy of acyclovir, an anti-viral drug, in the treatment of pityriasis rosea.A randomized, double-blind, placebo-controlled study of efficacy of oral acyclovir in the treatment (...) of pityriasis rosea was conducted on 73 patients. Thirty eight randomly selected patients were started on oral acyclovir. Thirty-five patients were prescribed placebo. The patients as well as the chief investigator were unaware of the therapeutic group to which patients belonged (acyclovir or placebo). Patients in both the groups were evaluated clinically after 7 and 14 days following the first visit and the data were analysed.Follow up data of 60 patients was available and these were included

2014 Journal of clinical and diagnostic research : JCDR PubMed

40. Recurrent and persistent pityriasis rosea: an atypical case presentation (Full text)

Recurrent and persistent pityriasis rosea: an atypical case presentation We report a case of atypical pityriasis rosea in a 24-year-old Malay man. He presented with an 11-month history of three recurrent and persistent episodes of pityriasis rosea associated with oral ulcers. The first episode lasted for one month and recurred within 14 days. The second episode lasted for three months and recurred within nine days. The third episode lasted for seven months. Although all three episodes were (...) not preceded by any prodromal symptoms, a herald patch was noted on three different sites (the left iliac fossa, abdomen and chest) on each successive episode. Recurrent pityriasis rosea and its association with oral ulcers, although quite uncommon, have been reported in the literature. However, reports of multiple recurrences, with prolonged duration of each episode and very short remissions in between, have not been made. To the best of our knowledge, this is the first report of such unique presentation.

2014 Singapore medical journal PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>